Drug
Pegvisomant clinical trials
Also written Somavert.
- studies test it
- 24
- open now
- 1
- in phase 3
- 5
- first study started
- 2001
Keep track of what changes. Save the pegvisomant studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Brand
Development codes
Combined with it in one product
Studies by the year they started
24 studies that test it; most in 2006 (5)
| Year | Studies |
|---|---|
| 2001 | 1 |
| 2003 | 2 |
| 2004 | 1 |
| 2005 | 1 |
| 2006 | 5 |
| 2008 | 1 |
| 2009 | 2 |
| 2010 | 2 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 2 |
| 2017 | 1 |
| 2019 | 1 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 2
- 2
- Phase 3
- 5
- Phase 4
- 7
- No phase
- 8
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 7 · Other 17
Pfizer (5) · University of Aarhus (4) · Cedars-Sinai Medical Center (2) · Erasmus Medical Center (2) · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (1) · Ipsen (1) · Unity Health Toronto (1) · Vanderbilt University (1)
Often tested with
Tested in the same studies.
Octreotide (3) · Human Growth Hormone (3) · Lanreotide (1) · Omega-N-Methylarginine (1) · Avexitide (1) · Cabergoline (1) · Figitumumab (1)
Studies
Open first, then newest update. How each study uses pegvisomant is read from its arms, and is right about nine times in ten.
Testing it · 24
- Study of Growth Hormone Inhibition Using Pegvisomant in Severe Insulin ResistanceRecruitingPhase 2National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NCT05470504Written as Pegvisomant
- Safety and Efficacy of Pegvisomant in Children With Growth Hormone ExcessCompletedPhase 3Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)NCT03882034Written as Pegvisomant
- Acromegaly Combination Treatment StudyTerminatedNot applicableCedars-Sinai Medical CenterNCT01538966Written as Pegvisomant
- Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic PatientsCompletedPhase 3IpsenNCT00383708Written as Pegvisomant
- Strict IGF-1 Control in AcromegalyCompletedPhase 3Unity Health TorontoNCT02952885Written as Pegvisomant
- Effect of DPP4 Inhibition on Growth Hormone SecretionCompletedPhase 4Vanderbilt UniversityNCT01701973Written as Pegvisomant
- Tissue Biomarker for Pegvisomant ActionCompletedNot applicableCedars-Sinai Medical CenterNCT01261000Written as Pegvisomant
- Role of Growth Hormone Antagonism in Modulating Insulin Sensitivity in Subjects With Pre-diabetesCompletedPhase 2University of California, San FranciscoNCT02023918Written as pegvisomant
- Efficacy of Octreotide Acetate and Cabergoline in Patients With AcromegalyCompletedPhase 4Novartis PharmaceuticalsNCT00376064Written as Octreotide acetate and cabergoline/Octrotide and Somavert
- Substrate Metabolism, Growth Hormone Signaling, and Insulin Sensitivity During FastingCompletedNot applicableUniversity of AarhusNCT02500095Written as Pegvisomant
- Pasireotide LAR and Pegvisomant Study in AcromegalyStatus unknownPhase 4Erasmus Medical CenterNCT02668172Written as Pegvisomant
- Figitumumab Combined With Pegvisomant For Advanced Solid TumorsTerminatedPhase 1PfizerNCT00976508Written as pegvisomant
- Pegvisomant With Glucagon Test to Assess for Adult Growth Hormone DeficiencyStatus unknownNot applicableOregon Health and Science UniversityNCT01804413Written as Pegvisomant
- Co-treatment With Pegvisomant and a Somatostatin Analogue (SA) in SA-responsive Acromegalic PatientsCompletedNot applicableUniversity of AarhusNCT00652379Written as Pegvisomant
- Safety, Tolerability and Relative Bioavailability of Pegvisomant in Healthy SubjectsCompletedPhase 1PfizerNCT01181973Written as pegvisomant
- Changes of Left Ventricular Mass and Cardiac Function in Patients With Active Acromegaly During Treatment With the Growth Hormone Receptor Antagonist PegvisomantStatus unknownPhase 4University of WuerzburgNCT00552851Written as pegvisomant
- The Relationship Between the Growth Hormone (GH)- Insulin Like Growth Factor I (IGF-I) System and the Inflammatory System in Healthy Normal PersonsStatus unknownNot applicableHerlev HospitalNCT00969644Written as Pegvisomant
- Growth Hormone During Fasting.Signaltransduktion in Muscle and Adipose Tissue and Changes in Intrahepatic Lipid ContentCompletedNot applicableUniversity of AarhusNCT00476879Written as Somatropin and pegvisomant
- Long Term Study With B2036-PEGCompletedPhase 3PfizerNCT00143416Written as Pegvisomant
- Pegvisomant And Sandostatin LAR Combination StudyCompletedPhase 4PfizerNCT00068029Written as Pegvisomant/ Sandostatin LAR
See all 24 studies that test pegvisomant →
Given in every arm · 1 — pegvisomant is usual care beside what is tested
Codes
What other systems call pegvisomant · ClinicalTrials.gg INT004226
- MeSH (NLM) C406545pegvisomantOne source NLM
- UNII (FDA) N824AOU5XVPEGVISOMANTConfirmed FDA, NLM, Wikidata
- RxNorm 278739Confirmed FDA, Wikidata
- Wikidata Q409697pegvisomantConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C61881PegvisomantOne source FDA
- DrugBank DB00082One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C406545 | pegvisomant | One source NLM |
| UNII (FDA) | N824AOU5XV | PEGVISOMANT | Confirmed FDA, NLM, Wikidata |
| RxNorm | 278739 | — | Confirmed FDA, Wikidata |
| Wikidata | Q409697 | pegvisomant | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C61881 | Pegvisomant | One source FDA |
| DrugBank | DB00082 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.